Pierre Fabre Medicament
Privately held: no public share price · France
Assets
(7 total)
7Total Assets
3Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | MEK1/2Small molecule | Non-Small Cell Lung CancerMelanoma | |
| Approved | BRAF V600ESmall molecule | Non-Small Cell Lung CancerColorectal CancerMelanoma Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer | |
| Approved | EGFR/HER2Small molecule | Non-Small Cell Lung CancerBreast Cancer HER2-Positive Breast Cancer | |
| Phase 1/2 | EGFR/HER2Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | METMonoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | RAFSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
No financial reports recorded.